Analysis of prescriptive monitoring regarding the current therapeutic landscape of rheumatoid arthritis: the experience of an Italian local health authority
The costs of RA may represent a significant spending commitment for central governments. As a result, actions are needed to encourage the preferential use of biosimilar drugs.
Authors
- Ferdinando Primiano
- Eduardo Nava (ORCID: https://orcid.org/0000-0003-3259-0511)
- Francesco Comentale
- Giuseppe Russo (ORCID: https://orcid.org/0000-0002-7078-1311)
- Francesco Ferrara (ORCID: https://orcid.org/0000-0001-9298-6783)
- Roberto Langella (ORCID: https://orcid.org/0000-0002-9272-8423)
- Ugo Trama (ORCID: https://orcid.org/0000-0001-9473-8943)
- Maurizio Capuozzo (ORCID: https://orcid.org/0000-0001-9488-6057)
- Andrea Zovi (ORCID: https://orcid.org/0000-0002-6528-2171)
Institutions
- Ministero della Salute (IT)
- Regione Campania (IT)
- Regional Health (US)
- Azienda Ospedaliero Universitaria Ospedali Riuniti (IT)
- Regione Lombardia
Publication Details
- Journal
- Expert Review of Pharmacoeconomics & Outcomes Research
- Published
- 2024-09-28
- DOI
- https://doi.org/10.1080/14737167.2024.2411431
- Citations
- 2
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.94